› Forums › Ocular Melanoma Community › chridal melanoma metastses to liver help needed.
- This topic has 14 replies, 4 voices, and was last updated 12 years, 8 months ago by
Teodora.
- Post
-
- August 11, 2011 at 8:34 am
A newcomer came into chat from Denver and needs help for a friend that has ocular melanoma that has gone to her lever. She has failed TACE and Ipi. She had allergic reaction to the yervoy so is on prednisone right now. She has dropped weight and lost hair & appeqrs ok outwardly but has a new tumor and another one getting larger.
She needs help with reearch.
I have some questions about what type mutations have been discovered in this type melanoma and what other trials, drugs might help.
A newcomer came into chat from Denver and needs help for a friend that has ocular melanoma that has gone to her lever. She has failed TACE and Ipi. She had allergic reaction to the yervoy so is on prednisone right now. She has dropped weight and lost hair & appeqrs ok outwardly but has a new tumor and another one getting larger.
She needs help with reearch.
I have some questions about what type mutations have been discovered in this type melanoma and what other trials, drugs might help.
Thank you for helping this lady. I hope to get to visit them when ic Colorado during the net couple of months. My dial p is too slow and I am running out of time to get reaedy to leave for Colorado.
- Replies
-
-
- August 11, 2011 at 11:13 am
Someone else may be of better help. But there are a number of mutations she can be tested for ie NRAS, BRAF and then have a targeted treatment for one of these. There is IL-2 or many people are talking about PD-1 which I think is a close relative of ipi. I am sure someone else will post more about these choices. Good luck to your friend.
-
- August 11, 2011 at 11:13 am
Someone else may be of better help. But there are a number of mutations she can be tested for ie NRAS, BRAF and then have a targeted treatment for one of these. There is IL-2 or many people are talking about PD-1 which I think is a close relative of ipi. I am sure someone else will post more about these choices. Good luck to your friend.
-
- August 11, 2011 at 12:49 pm
In the past, I think most ocular melanoma patients have found help elsewhere as there isn't much of that on this board. I do know that someone once recommended http://www.eyecancer.com as a good place to start.
Janner
p.s. Stay off of horses, Jerry!
-
- August 11, 2011 at 12:49 pm
In the past, I think most ocular melanoma patients have found help elsewhere as there isn't much of that on this board. I do know that someone once recommended http://www.eyecancer.com as a good place to start.
Janner
p.s. Stay off of horses, Jerry!
-
- August 11, 2011 at 12:51 pm
Hi Jerry,
Doesn't ocular melanoma qualify as mucosal too?
Regarding specific permutations in mucosal, when discussing my slides being tested, Dr.Hodi was very dismissive about the possibility to have NRAS or any other gene mutation /BRAF excluded 100%/, except the C-kit /if any at all/.
My impression is that they don't have high expectation for any specific permutations being found in mucosal at all in most of the cases,and having the C-kit is rather exception.Consider yourself lucky/smile/.
Teodora
-
- August 11, 2011 at 2:38 pm
I have seen nothing refering yo uveal as being Mucousal, but the followig does indicaate a ssimilar -kit rlationship.
ttp://en.wikipedia.org/wiki/Uveal_melanoma
Read the entire article. #
Uveal melanoma is distinct from most skin melanomas associated with ultraviolet exposure; however, it shares several similarities with non-sun-exposed melanomas, such as acral melanomas and mucosal melanomas. BRAF mutations are extremely rare in posterior uveal melanomas;[5] instead, uveal melanomas frequently harbor GNAQ/GNA11 mutations, a trait shared with blue nevi, Nevus of Ota, and Ocular melanosis.[6][7] As seen in BRAF, mutations in GNAQ/GNA11 are early events in tumorigenesis and are not prognostic for tumor stage or later metastatic spread.[8] In contrast, mutations in the gene BAP1 are strongly linked to metastatic spread and patient survival.[9
*********************************Expression of c-Kit and its ligand SCF in primary uveal melanoma
Jan 28, 2011 – To evaluate the concurrent rate of expression of c-Kit and its ligand stem cell factor (SCF) in uveal melanoma in respect to the further …
****************************************************************************************************
***http://digitool.library.mcgill.ca/R/?func=dbin-jump-full&object_id=14187&local_base=GEN01-MCG02
********BACKGROUND:Uveal melanoma (UM) is the most common primary intraocular tumor in adults, leading to metastasis in 40% of the cases and ultimately to death in 10 years, despite local and/or systemic treatment. The c-kit protein (CD117) is a membrane-bound tyrosine kinase receptor and its overexpression has been observed in several neoplasms. Imatinib mesylate is a FDA approved compound that inhibits tyrosine quinase receptors, as well as c-kit. Imatinib mesylate controls tumor growth in up to 85% of advanced gastrointestinal stromal tumors, a neoplasia resistant to conventional therapy.METHODS:Fifty-five specimens of primary UM selected from the archives of the Ocular Pathology Laboratory, McGill University, Montreal, Canada, were immunostained for c-kit. All cells displaying distinct immunoreactivity were considered positive. Four human UM cell lines and 1 human uveal transformed melanocyte cell line were tested for in vitro proliferation Assays (TOX-6) and invasion assay with imatinib mesylate (concentration of 10 µM).RESULTS:The c-kit expression was positive in 78.2% of the UM. There was a statistical significant decrease in the proliferation and invasion rates of all 5 cell lines.CONCLUSION:The majority of UM expressed c-kit, and imatinib mesylate does decrease the proliferation and invasion rates of human UM cell lines. These results justify the need for a clinical trial to investigate in vivo the response of UM to imatinib mesylate.******************************************************
-
- August 11, 2011 at 2:38 pm
I have seen nothing refering yo uveal as being Mucousal, but the followig does indicaate a ssimilar -kit rlationship.
ttp://en.wikipedia.org/wiki/Uveal_melanoma
Read the entire article. #
Uveal melanoma is distinct from most skin melanomas associated with ultraviolet exposure; however, it shares several similarities with non-sun-exposed melanomas, such as acral melanomas and mucosal melanomas. BRAF mutations are extremely rare in posterior uveal melanomas;[5] instead, uveal melanomas frequently harbor GNAQ/GNA11 mutations, a trait shared with blue nevi, Nevus of Ota, and Ocular melanosis.[6][7] As seen in BRAF, mutations in GNAQ/GNA11 are early events in tumorigenesis and are not prognostic for tumor stage or later metastatic spread.[8] In contrast, mutations in the gene BAP1 are strongly linked to metastatic spread and patient survival.[9
*********************************Expression of c-Kit and its ligand SCF in primary uveal melanoma
Jan 28, 2011 – To evaluate the concurrent rate of expression of c-Kit and its ligand stem cell factor (SCF) in uveal melanoma in respect to the further …
****************************************************************************************************
***http://digitool.library.mcgill.ca/R/?func=dbin-jump-full&object_id=14187&local_base=GEN01-MCG02
********BACKGROUND:Uveal melanoma (UM) is the most common primary intraocular tumor in adults, leading to metastasis in 40% of the cases and ultimately to death in 10 years, despite local and/or systemic treatment. The c-kit protein (CD117) is a membrane-bound tyrosine kinase receptor and its overexpression has been observed in several neoplasms. Imatinib mesylate is a FDA approved compound that inhibits tyrosine quinase receptors, as well as c-kit. Imatinib mesylate controls tumor growth in up to 85% of advanced gastrointestinal stromal tumors, a neoplasia resistant to conventional therapy.METHODS:Fifty-five specimens of primary UM selected from the archives of the Ocular Pathology Laboratory, McGill University, Montreal, Canada, were immunostained for c-kit. All cells displaying distinct immunoreactivity were considered positive. Four human UM cell lines and 1 human uveal transformed melanocyte cell line were tested for in vitro proliferation Assays (TOX-6) and invasion assay with imatinib mesylate (concentration of 10 µM).RESULTS:The c-kit expression was positive in 78.2% of the UM. There was a statistical significant decrease in the proliferation and invasion rates of all 5 cell lines.CONCLUSION:The majority of UM expressed c-kit, and imatinib mesylate does decrease the proliferation and invasion rates of human UM cell lines. These results justify the need for a clinical trial to investigate in vivo the response of UM to imatinib mesylate.******************************************************
-
- August 11, 2011 at 3:04 pm
As a matter of fact you are 100% right.
I always thought since mucosal is a " wet tissue" cancer, ocular is similar.Actually, mucosal, ocular and cutaneous are 3 totally different "animals".
"When melanoma occurs on the skin it is known as cutaneous melanoma; in the mucous membranes, it is know as mucosal melanoma, and when it occurs in the eye it is known as ocular melanoma. Despite their common origins – all melanomas are ultimately cancers of the melanocytes – ocular, mucosal and cutaneous mucosal melanoma are separate diseases with different patterns of development and different clinical courses."
Teodora
-
- August 11, 2011 at 3:04 pm
As a matter of fact you are 100% right.
I always thought since mucosal is a " wet tissue" cancer, ocular is similar.Actually, mucosal, ocular and cutaneous are 3 totally different "animals".
"When melanoma occurs on the skin it is known as cutaneous melanoma; in the mucous membranes, it is know as mucosal melanoma, and when it occurs in the eye it is known as ocular melanoma. Despite their common origins – all melanomas are ultimately cancers of the melanocytes – ocular, mucosal and cutaneous mucosal melanoma are separate diseases with different patterns of development and different clinical courses."
Teodora
-
- August 11, 2011 at 12:51 pm
Hi Jerry,
Doesn't ocular melanoma qualify as mucosal too?
Regarding specific permutations in mucosal, when discussing my slides being tested, Dr.Hodi was very dismissive about the possibility to have NRAS or any other gene mutation /BRAF excluded 100%/, except the C-kit /if any at all/.
My impression is that they don't have high expectation for any specific permutations being found in mucosal at all in most of the cases,and having the C-kit is rather exception.Consider yourself lucky/smile/.
Teodora
-
- August 11, 2011 at 2:40 pm
Jerry,
I just came across this atricle on Uveal /ocular/ Melanoma with Metastases to the Liver.
http://www.lafn.org/~bc534/OcularMelMets.htm
If you can forward it to her friend/her, they might find this information helpful.
Teodora
-
- August 11, 2011 at 2:40 pm
Jerry,
I just came across this atricle on Uveal /ocular/ Melanoma with Metastases to the Liver.
http://www.lafn.org/~bc534/OcularMelMets.htm
If you can forward it to her friend/her, they might find this information helpful.
Teodora
-
- You must be logged in to reply to this topic.